Authors : Pratibha Bhide; Ankita Tiwari; Abhishek Nagar; Manish Shakya

Volume/Issue : Volume 9 - 2024, Issue 5 - May

Google Scholar : https://tinyurl.com/2788tsex

Scribd : https://tinyurl.com/249dx6ts

DOI : https://doi.org/10.38124/ijisrt/IJISRT24MAY1009

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Abstract : Autoimmune blistering diseases, such as Linear IgA Bullous Dermatosis (LABD) and Chronic Bullous Disease of Childhood (CBDC), provide considerable therapeutic treatment issues. Samana Aushadhis are regularly prescribed by Ayurvedic practitioners as part of therapy regimens for dermatological diseases including LABD and CBDC. Although anecdotal data and clinical observations point to the potential usefulness of traditional medicines in promoting long-term remission and alleviating symptoms, the precise mechanisms by which they exert their therapeutic benefits in LABD/CBD remain incompletely known in contemporary science. The potential advantages of traditional therapies in autoimmune blistering illnesses are being investigated through clinical trials, observational research, and mechanistic investigations. The therapeutic potential of these herbal remedies in LABD and CBDC is being investigated through clinical trials, observational research, and mechanistic investigations. Clinical trials, observational studies, and mechanistic investigations are being conducted in an effort to better understand the therapeutic potential of conventional medications in autoimmune blistering disorders. The effectiveness of these herbal treatments in causing remission and easing symptoms in LABD and CBDC is being closely examined. Overall, while traditional therapies hold promise in the management of autoimmune blistering diseases like LABD and CBDC, more research is necessary to fully understand their mechanisms of action and therapeutic potential. Through rigorous scientific inquiry, the integration of traditional and contemporary medicine may offer new avenues for managing these difficult conditions. Clinical trials, observational research, and mechanistic investigations are all contributing to the exploration of the therapeutic potential of these herbal remedies in LABD and CBDC.

Keywords : Autoimmune Blistering, LABD, CBDC, Traditional Indian Medical System.

References :

1. Singh, S., Gautam, R., & Gautam, A. (2018). Role of Samana Aushadhis in the Management of Chronic Bullous Diseases of Childhood and Linear IgA Bullous Dermatosis: A Review. Journal of Pharmaceutical Sciences and Research, 10(7), 1599-1603.
2. Sharma, R. K., Dash, B., & Agnivesha. (2009). Astanga Hrdayam of Vagbhata: Sutrasthana. Chowkhamba Krishnadas.  Academy.
3. Rathi, S. K., Kumaresan, M., & Sahoo, B. (2019), A comprehensive review on the management of Chronic Bullous Diseases of Childhood and Linear IgA Bullous Dermatosis in Ayurveda.  International Journal of Research in Ayurveda and Pharmacy, 10(1): 92-96.
4. Rao, G. S., & Sahu, J. (2016). Efficacy of Ayurvedic formulations in the management of Chronic Bullous Diseases of Childhood: A case study. International Journal of Ayurveda and Pharma Research, 4(10), 54-57.
5. Arpita Nandi, Sukumar Ghosh, Role of Ayurveda Chikitsha Siddhanta in the Management of Amavata W.S.R. to Rheumatoid Arthritis - A Case Study.  Int. Res J. Ayur. Yoga 2023. 6(12), pp. 59-63.
6. Sharma AK. Kayachikitsa Part 3. Amavata Adhayaa. Varanasi: Chaukhambha Orientalia; 2014. p. 147.
7. Sharma J. Chakradatta. Aamvatadhikar. Bombay: Shri Laxmi Venkateshwar Steam Press; 2002. p. 131.
8. Sastri S. Madhava Nidhan Amavatanidanam 25/1. Varanasi: Chaukhamba Prakashan; 2007. p.510.
9. Mishra M. Vivid action of simhanada guggulu in the management of amavata (Rheumatoid arthritis): A review. Int J Health Sci Res 2021;11: pp.126-9.
10. E. Kondorosi, P. Mergaert, A. Kereszt, A paradigm for endosymbiotic life: Cell differentiation of Rhizobium bacteria provoked by host plant factors. Annu. Rev. Microbiol. 2013. 67, pp. 611–628.
11. G. Maróti, J. A. Downie, É. Kondorosi, Plant cysteine-rich peptides that inhibit path ogen growth and control rhizobial differentiation in legume nodules. Curr. Opin. Plant Biol. 26, 2015 pp. 57–63.
12. Frank Tietze, Pratheeba Vimalnath. Crisis-Critical Intellectual Property: Findings From the COVID-19 Pandemic, IEEE Transections on engineering management.69, 2022. Pp. 5.
13. Mortality Analyses, Johns Hopkins Coronavirus Resource Center. Ac cessed: May 11, 2020. [Online]. Available: https://coronavirus.jhu.edu/ data/mortality
14.  Worldometer, Worldometer COVID-19 Pandemic, Worldometer. Ac cessed: May 12, 2020. [Online]. Available: https://www.worldometers. info/coronavirus/?utm_campaign = homeAdvegas1?%22
15. N. L. van der Weerden, M. R. Bleackley, M. A. Anderson, Properties and mechanisms of action of naturally occurring antifungal peptides. Cell. Mol. Life Sci. 70, 3545–3570 (2013).
16. G. Steinberg et al., A lipophilic cation protects crops against fungal pathogens by multiple modes of action. Nat. Commun. 11, 1608 (2020).
17. E. Kondorosi, P. Mergaert, A. Kereszt, A paradigm for endosymbiotic life: Cell dif ferentiation of Rhizobium bacteria provoked by host plant factors. Annu. Rev. Mi crobiol. 67, 611–628 (2013).
18. Shabnam Bano, Dilawer, Management of Amavata w.s.r to Rheumatoid Arthritis-A Case Report, International Research Journal of Ayurveda & Yoga Vol. 5 (2),74-77, February, 2022.
19. Tripathi I, Sri Chakrapanidatta’s Chakradutta with Vaidaya- prabha, Hindi Commentary Chapter 73, Niruhadhikar 73/32Varanasi, Chaukambha Sanskrit Bhawan, reprint edition, 2018.pp.455.
20. 20. Dr. Rahul Ishwarlal Desai, Dr. Vijayalaxmi Sujay Patil and Dr. Harshada Suhas Phate, A Case study on Amavata W.S.R. To rheumatoid arthritis, wjpmr, 2024, 10(2), 191-194.
21. Shah Ankur, E.William St. Clair, Harrison's Principles of Internal Medicine Volume 2, 18th edition, Chapter 321, Rheumatoid Arthritis, 2739.
22. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis & Rheumatism Arthritis & Rheumatism-Arthritis Care & Research, 1988; 31(3): 315-324.
23. Das Govinda, Bhaisbajya Ratnavali, Hindi commentary by Ambikadatta Shastri, Chaukhambha Prakashana Varanasi Edition, Amavata chikitsa, 2014; 29/181-189: 628.
24. Madhavakara, Madhavnidan, Vimala Madhudhara Teeka by Tripathi Brahmanand, Chaukhambha Surabharati Prakashan, Varanasi, ed., poorvariha, adhyaya, 2010; 25: 571-577.
25. Schmidt E, Zillikens D. Pemphigoid diseases. Lancet. 2013;381(9863):320-332. doi:10.1016/S0140-6736(12)61140-4
26. Kasperkiewicz M, Ellebrecht CT, Takahashi H, et al. Pemphigus. Nat Rev Dis Primers. 2017;3:17026. doi:10.1038/nrdp.2017.26
27. Lamberts A, Euverman HI, Terra JB, et al. Immunopathology of bullous pemphigoid, mucous membrane pemphigoid and epidermolysis bullosa acquisita: complement and autoantibody updates. J Dermatol Sci. 2015;77(3):159-166. doi:10.1016/j.jdermsci.2014.11.006.
28. Murrell DF, Marinovic B, Caux F, et al. Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts. J Am Acad Dermatol. 2012;66(3):479-485. doi:10.1016/j.jaad.2011.03.023.
29. Kasperkiewicz M, Schmidt E, Zillikens D. Current therapy of the pemphigus group. Clin Dermatol. 2012;30(1):84-94. doi:10.1016/j.clindermatol.2011.04.016.
30. Roujeau JC, Chosidow O, Saiag P, Guillaume JC. Bullous pemphigoid, pemphigus, and epidermolysis bullosa acquisita: comparative histologic and immunologic findings. J Am Acad Dermatol. 1984;10(5 Pt 1):889-896. doi:10.1016/s0190-9622(84)80311-2.
31. Joly P, Maho-Vaillant M, Prost-Squarcioni C, et al. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet. 2017;389(10083):2031-2040. doi:10.1016/S0140-6736(17)30070-3
32. Ahmed AR, Spigelman Z, Cavacini LA, Posner MR. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med. 2006;355(17):1772-1779. doi:10.1056/NEJMoa062930
33. Amber KT, Valdebran M, Grando SA. Non-Desmoglein Antibodies in Patients with Pemphigus Vulgaris. Front Immunol. 2018;9:1190. doi:10.3389/fimmu.2018.01190
34. Chams-Davatchi C, Mortazavizadeh A, Daneshpazhooh M, et al. Randomized double blind trial of prednisolone and azathioprine, vs. prednisolone and placebo, in the treatment of pemphigus vulgaris. J Eur Acad Dermatol Venereol. 2013;27(10):1285-1292. doi:10.1111/jdv.12000